for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SAWAI PHARMACEUTICAL CO., LTD.

4555.T

Latest Trade

6,760.00JPY

Change

80.00(+1.20%)

Volume

82,400

Today's Range

6,670.00

 - 

6,780.00

52 Week Range

5,020.00

 - 

6,780.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6,680.00
Open
6,760.00
Volume
82,400
3M AVG Volume
3.22
Today's High
6,780.00
Today's Low
6,670.00
52 Week High
6,780.00
52 Week Low
5,020.00
Shares Out (MIL)
43.78
Market Cap (MIL)
297,115.30
Forward P/E
14.14
Dividend (Yield %)
1.93

Next Event

Q3 2020 Sawai Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

R&I removes Sawai Pharmaceutical from rating monitor and affirms its rating at "A-"-R&I

Sawai Pharmaceutical completes sale of 20 pct stake in Upsher-Smith Laboratories

SAWAI PHARMACEUTICAL says details of shares private placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SAWAI PHARMACEUTICAL CO., LTD.

SAWAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company mainly engaged in the manufacture and sale of ethical drugs and proprietary drugs. The Company operates in two segments. The Japan segment distributes its products through sales companies, wholesale shops and other pharmaceutical manufacturers, and also directly to medical institutions. The US segment manages subsidiaries in the US and sells manufactured pharmaceuticals to wholesalers in the US.

Industry

Biotechnology & Drugs

Contact Info

5-2-30, Miyahara, Yodogawa-ku

+81.6.61055711

https://www.sawai.co.jp/

Executive Leadership

Hiroyuki Sawai

Chairman of the Board, Representative Director

Mitsuo Sawai

President, Representative Director

Kenzo Sawai

Senior Managing Executive Officer, Director of Strategy Planning, President of Subsidiary, Director

Kazuhiko Sueyoshi

Managing Executive Officer, Chief Director of Administration, Director

Minoru Kodama

Managing Executive Officer, Director

Key Stats

2.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (JPY)

2017

431.650

2018

360.490

2019

442.620

2020(E)

476.668
Price To Earnings (TTM)
14.89
Price To Sales (TTM)
1.60
Price To Book (MRQ)
1.44
Price To Cash Flow (TTM)
8.03
Total Debt To Equity (MRQ)
38.65
LT Debt To Equity (MRQ)
35.56
Return on Investment (TTM)
7.11
Return on Equity (TTM)
5.35

Latest News

Latest News

BRIEF-R&I removes Sawai Pharmaceutical from rating monitor and affirms its rating at "A-"-R&I

* Rating and Investment Information, Inc. (R&I) removed the company from rating monitor-R&I

REFILE-TABLE-Sawai Pharmaceutical- 9-MTH group results

Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Dec 31, 2017 Dec 31, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 116.54 101.38 168.80 (+15.0 pct) (+9.7 pct...

BRIEF-Sawai Pharmaceutical completes sale of 20 pct stake in Upsher-Smith Laboratories

* Says 20 percent stake in Upsher-Smith Laboratories LLC, which was wholly owned by co's unit SAWAI AMERICA, LLC, has been transferred to SUMITOMO CORP's wholly owned US-based unit Sumitomo Corporation of Americas, on Jan. 3

BRIEF- Sawai Pharmaceutical to issue new shares and to distribute treasury common stock

* Says it plans to issue 5 million new shares and to distribute 1 million shares of its treasury common stock through public offering

REFILE-TABLE-Sawai Pharmaceutical- 6-MTH group results

Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2017 Sep 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 70.76 65.42 168.80 (+8.2 pct) (+11.0 pct...

BRIEF-Sawai Pharmaceutical to sell 20 pct stake in SAWAI AMERICA for $211 mln

* Says it plans to sell 20 percent stake in a wholly owned U.S.-based unit SAWAI AMERICA INC to Sumitomo Corporation of Americas, a wholly owned unit of SUMITOMO CORPORATION, for $211 million (23.2 billion yen)

BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

* Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan

REFILE-TABLE-Sawai Pharmaceutical-Q1 group results

Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 3 months ended 3 months ended Year to Jun 30, 2017 Jun 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 33.65 32.95      142.00 (+2.1 pct) (+12.1...

BRIEF- Sawai Pharmaceutical completes acquisition of Upsher-Smith Laboratories for $1.05 bln

* Says it acquired U.S.-based company Upsher-Smith Laboratories, LLC, which is engaged in manufacture and sales of generic drug, for $1.05 billion (about 116.5 billion yen), on May 31 (U.S. local time)

REFILE-TABLE-Sawai Pharmaceutical-2016/17 group results

Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2017 Mar 31, 2016 Mar 31, 2018 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 132.43 123.49 142.00...

BRIEF-Sawai Pharmaceutical announces application of IFRS

* Says it plans to apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles

BRIEF- R&I places Sawai Pharmaceutical on rating monitor with view to downgrading-R&I

* Rating and Investment Information, Inc. (R&I) put the company on rating monitor with view to downgrading

Japan's Sawai buys U.S. firm Upsher-Smith's generic drugs unit for $1.1 billion

Japan's Sawai Pharmaceutical Co Ltd <4555.T> is buying the generic drug business of U.S. drug maker Upsher-Smith Laboratories Inc for $1.05 billion, marking the Osaka-based generic drugmaker's first overseas acquisition.

Japan's Sawai Pharmaceutical to buy U.S.'s Upsher-Smith Laboratories for $1.05 bln

Japan's Sawai Pharmaceutical Co Ltd said on Thursday it would buy U.S. generic drug maker Upsher-Smith Laboratories Inc for $1.05 billion in its first overseas acquisition.

BRIEF-Sawai Pharma to buy Upsher-Smith Laboratories for $1.05 bln

* Says to buy Upsher-Smith Laboratories for $1.05 billion Source text for Eikon in Japanese: Further company coverage: (Reporting By Chris Gallagher)

BRIEF-Yungjin Pharm signs 181.56 bln won contract with Sawai Pharmaceutical

* Says it signed 181.56 billion won contract with Sawai Pharmaceutical Co Ltd to provide medicine

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up